Global Artificial Heart Valve Market Size By Type (Transcatheter Heart Valves, Tissue Heart Valves), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Artificial Heart Valve Market was valued at USD 8.1 billion in 2023 and is projected to reach USD 15.6 billion by 2031, expanding at a CAGR of 8.5% over the forecast period. The market is primarily driven by the increasing prevalence of cardiovascular diseases, advancements in valve technologies, and the rising geriatric population globally. Artificial heart valves play a critical role in managing valvular heart diseases, with growing adoption of transcatheter aortic valve replacement (TAVR) procedures significantly accelerating market growth.

Drivers:

1. Rising Prevalence of Cardiovascular Diseases:

Cardiovascular disorders, especially valvular heart diseases such as aortic stenosis and mitral regurgitation, are increasing due to aging populations and lifestyle changes. This is leading to a surge in the demand for artificial heart valve replacements.

2. Advancements in Valve Technologies:

Technological innovations, including minimally invasive procedures like TAVR and next-generation bioprosthetic valves, are improving patient outcomes, reducing hospital stays, and expanding eligibility for high-risk patient groups.

3. Growth in Geriatric Population:

The growing elderly population, particularly in developed regions, is a key demographic for heart valve replacement surgeries, contributing significantly to the demand for artificial valves.

Restraints:

1. High Cost of Valve Replacement Procedures:

The cost of artificial heart valves and associated surgical procedures remains high, limiting accessibility in lower-income regions and posing a significant barrier for healthcare systems with constrained budgets.

2. Risk of Complications:

Despite technological progress, complications such as valve degeneration, infection, and thrombosis persist, which can deter adoption and affect patient trust in artificial valves.

Opportunity:

1. Expanding Access to TAVR in Emerging Markets:

TAVR, once limited to high-income countries, is gradually being introduced in emerging economies. With improving healthcare infrastructure and policy support, these regions present a lucrative growth opportunity.

2. Personalized Valve Development:

The future of artificial heart valve technology lies in personalization—developing valves tailored to individual patient anatomies using 3D printing and AI-based modeling, offering better fit and performance.

Market by System Type Insights:

Based on system type, Transcatheter Heart Valves dominated the market in 2023 due to their increasing preference over surgical alternatives for high-risk patients. Their minimally invasive nature, reduced recovery time, and positive clinical outcomes are propelling segment growth. Mechanical Valves also hold a significant share, favored for their durability, especially in younger patients.

Market by End-use Insights:

In terms of end-use, Hospitals accounted for the largest market share in 2023, driven by the availability of advanced surgical infrastructure and skilled professionals. Ambulatory Surgical Centers (ASCs) are emerging rapidly as an alternative setting, offering cost-effective and efficient valve replacement services.

Market by Regional Insights:

North America led the global artificial heart valve market in 2023, driven by a high prevalence of cardiovascular disorders, advanced healthcare systems, and the strong presence of market leaders. Asia-Pacific is expected to witness the fastest growth during the forecast period, attributed to rising healthcare investments, improving diagnostic capabilities, and increasing awareness of heart health in countries like China and India.

Competitive Scenario:

Key players in the global artificial heart valve market include:

Edwards Lifesciences Corporation

Medtronic plc

Abbott Laboratories

Boston Scientific Corporation

LivaNova PLC

CryoLife, Inc.

JenaValve Technology, Inc.

Colibri Heart Valve LLC

These companies are focusing on developing innovative transcatheter valve solutions, expanding clinical indications, and forming strategic partnerships to strengthen their market presence.

Scope of Work – Global Artificial Heart Valve Market

Report Metric Details

Market Size (2023) USD 8.1 billion

Projected Market Size (2031) USD 15.6 billion

CAGR (2023-2031) 8.5%

Market Segments By System Type (Mechanical, Biological, Transcatheter), By End-use (Hospitals, Ambulatory Surgical Centers), By Region

Growth Drivers Rising prevalence of heart diseases, growth in elderly population, technological advancements

Opportunities TAVR penetration in emerging markets, personalized and minimally invasive valve solutions

Key Market Developments:

2023: Edwards Lifesciences received expanded FDA approval for its SAPIEN 3 Ultra Resilia valve, aimed at younger, lower-risk patients.

2024: Medtronic launched a next-gen Evolut FX transcatheter aortic valve in Europe, enhancing precision and control during implantation.

2025: Boston Scientific announced the acquisition of a cardiac innovation start-up focused on mitral valve repair technologies.

FAQs:

1. What is the current market size of the Global Artificial Heart Valve Market?

The market was valued at USD 8.1 billion in 2023.

2. What is the major growth driver of the Global Artificial Heart Valve Market?

The major growth driver is the rising prevalence of cardiovascular diseases, especially among the aging population.

3. Which is the largest region during the forecast period in the Global Artificial Heart Valve Market?

North America remains the largest region during the forecast period.

4. Which segment accounted for the largest market share in the Global Artificial Heart Valve Market?

The Transcatheter Heart Valves segment held the largest share in 2023.

5. Who are the key market players in the Global Artificial Heart Valve Market?

Key players include Edwards Lifesciences, Medtronic, Abbott, Boston Scientific, and LivaNova, among others.